Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Phase III, NSABP, STAR, Activated 5/21/99
 
Eligibility Requirements:
 
Postmenopausal woman
 
At least 35 years old
 
At increased risk for developing breast cancer (at least 1.66% 5-year risk as determined by NSABP Breast Cancer Risk Assessment Profile or histologic diagnosis of LCIS treated by lumpectomy only)
 
At least 10 years life expectancy
 
No prior or suspected invasive breast cancer or DCIS
 
No prior mastectomy
 
No participation in other cancer prevention or osteoporosis prevention study (NSABP P-1 participation okay if on placebo)
 
No prior malignancy that occurred less than 5 years prior, except non-melanoma skin cancer
 
No prior history of deep-vein thrombosis or pulmonary embolus
 
No prior history of documented cerebral vascular accident or transient ischemic attack
 
No HRT, oral contraceptives, androgens, LHRH, or antiestrogens (if discontinue at least 3 months before randomization okay)
 
No prior tamoxifen, raloxifene or other SERM (if received drug <3 months and discontinue at least 3 months before randomization okay)
 
 
William Jewell, M.D., is the Principal Investigator for this study. Please contact Brooke Groneman for more information or for patient registration: (913) 588-4719 or toll free (877) 253-4477.